Peptide therapeutics that meet the challenges of modern medicine

Endevica’s novel peptidomimetics overcome the current limitations of small molecules, antibodies and other modalities to treat conditions safely, effectively and with minimal side effects.

cachexia Obesity

Endevica Bio is committed to pioneering science-driven solutions in peptide therapeutics. These groundbreaking therapies will transform patient outcomes in cancer cachexia and metabolic disorders.

Cachexia

Cancer cachexia drug, TCMCB07, has started an innovative Phase 2 trial in 2025 that will redefine the standard of care in oncology.

Learn More

Obesity

Weight loss drug, 710GO, reduces weight of obese non-human primates by 11.7% over 15 weeks without GLP-1-like side effects.

Learn More

“Endevica Bio is transforming patient care while unlocking oncology and metabolic disorder market opportunities.”

Russell Potterfield
CEO of Endevica Bio

Latest News

View More

Latest Publications

View More